Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA5108 Ocular Implant in Open Angle Glaucoma
NCT03604328Phase 1Completed
- Sponsor
- PolyActiva
- Start
- Jul 2018
- Primary completion
- Jun 2020
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PA5108 Latanoprost FA SR Ocular Implant in open-angle glaucoma (OAG), sponsored by PolyActiva. Primary endpoint: Occurrence of Adverse Events at 4 weeks. Started Jul 2018; status: completed.
02
Drugs
PA5108 Latanoprost FA SR Ocular Implant
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT03604328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03604328.